Article info
PDFOriginal Article
Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
- Dr F Prager, Department of Ophthalmology, Medical University of Vienna, Waehringer Guertel 18-20, 1190 Wien, Austria; franz.prager{at}meduniwien.ac.at
Citation
Intravitreal bevacizumab (Avastin®) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
Publication history
- Accepted November 9, 2008
- First published December 15, 2008.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2009 BMJ Publishing Group Ltd